The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Anovo robotic surgery platform, developed by Momentis Surgical, for repairing ventral hernias. This approval adds to the company's existing FDA clearances for gynecological procedures performed transvaginally.
Momentis Surgical has developed a compact, mobile robotic system for various surgeries that operates through a single entry point. Anovo is the only robotic platform in the world approved by the FDA for minimally invasive abdominal hernia repair using just one entry incision. The system is distinguished by its robotic arms, which resemble human arms, equipped with joints capable of 360-degree rotation and flexibility across multiple planes. Several surgical instruments can be inserted through a single entry point.
Momentis Surgical focuses on developing cutting-edge, miniaturized robotic technologies for an expanding range of medical applications, aiming to improve surgical outcomes, reduce costs, and increase access to robotic-assisted surgeries.
Dvir Cohen, CEO and co-founder of Momentis, said: "We leveraged the clinical success of the Anovo platform in gynecology to expand into general surgery. Its size and mobility make the system suitable for both hospitals and physician clinics."
Eyal Lifshitz, managing partner at Peregrine Venture Capital, added: "Momentis has achieved significant milestones in the past year to broaden the clinical capabilities of its robotic system."
Professor Yoav Mintz from Hadassah Medical Center stated: "The Momentis robot offers a unique approach to robotic surgery. The flexible arms combined with a single entry point enhance maneuverability while ensuring a less invasive procedure."
Dr. Frederic H. Moll, a member of the Momentis board of directors, commented: "The company has now created a true robotic platform, making it a distinctive technology that will have an immediate impact on the way general surgery is performed."